Hengrui’s Docetaxel Use Ruled Not Infringing On Sanofi-Aventis’ Patent
This article was originally published in PharmAsia News
Executive SummaryHengrui China's Patent Re-examination Board of the State Intellectual Property Office (SIPO) has ruled that the patent right of Aventis Pharma S.A. and Sanofi-Aventis for Docetaxel is invalid. If dissatisfied with the verdict, the plaintiffs can appeal to the Beijing Number One Intermediate People's Court within three months. Last September, Aventis Pharma and Sanofi-Aventis sued Jiangsu Hengrui in Beijing Municipal Higher People's Court for Docetaxel patent infringement, asking for patent fees of 45 million yuan ($6.4 million), financial loss compensation of 55 million yuan ($7.87 million), miscellaneous expenses of 200,000 yuan ($28,000) and full cost of the litigation. (Click here for more - Chinese language)
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.